The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Portrait of Anna Glenngård. Photo.

Anna Glenngård

Assistant head Accounting and Corporate Finance, Department of Business Administration

Portrait of Anna Glenngård. Photo.

Patient preferences and willingness-to-pay for ADHD treatment with stimulants using discrete choice experiment (DCE) in Sweden, Denmark and Norway

Author

  • Anna Glenngård
  • Jonas Hjelmgren
  • Per Hove Thomsen
  • Torbjörn Tvedten

Summary, in English

Background: The choice between different attention-deficit/hyperactivity disorder (ADHD) medications depends on different drug attributes. Economic evaluations of drugs often disregard the utility of other attributes compare with the drugs' efficacy. Aims: The aim of this study was to assess patient's preferences and elicit willingness-to-pay (WTP) for different drug attributes in the treatment of ADHD. Methods: 285 patients (117 parents for children below 15 years, 52 adolescents 15-17 years and 116 adults aged 18 years and above) from Sweden, Denmark and Norway completed a questionnaire concerning their ADHD drug treatment, and answered questions on their preferences using a discrete choice experiment (DCE). Included attributes were effectiveness, side-effects, dosing and price. Results: Effectiveness was the most important attribute, followed by side-effects and the number of dosings per day (all P < 0.001). The estimated monthly WTP for a drug generating full effectiveness, no side-effects and once-daily dosing was €790 for adolescents and €360 for adults. The estimated WTP for ADHD drugs with characteristics similar to existing drugs on the market was higher or in line with market prices (€37-180 for adolescents and €16-80 for adults). Regarding experience with current treatment, 19% of all patients in the study reported good functioning during the morning, day and evening. Conclusions: The gap between the monetary valuation of existing products and an optimally valued product suggest that there is room for improvements in the clinical management of ADHD. The results suggest that DCE is a method that can be used to value not only hypothetical scenarios but also can be used to value and distinguish between real-life scenarios.

Publishing year

2013

Language

English

Pages

351-359

Publication/Series

Nordic Journal of Psychiatry

Volume

67

Issue

5

Document type

Journal article

Publisher

Informa Healthcare

Topic

  • Health Care Service and Management, Health Policy and Services and Health Economy

Keywords

  • ADHD
  • discrete choice experiment
  • patient preferences
  • willingness-to-pay

Status

Published

ISBN/ISSN/Other

  • ISSN: 1502-4725